Age-Associated Differences in Fatigue Among Patients with Cancer
|
|
- Henry McKinney
- 6 years ago
- Views:
Transcription
1 Vol. 40 No. 2 August 2010 Journal of Pain and Symptom Management 217 Original Article Age-Associated Differences in Fatigue Among Patients with Cancer Zeeshan Butt, PhD, Arati V. Rao, MD, Jin-Shei Lai, PhD, Amy P. Abernethy, MD, Sarah K. Rosenbloom, PhD, and David Cella, PhD Department of Medical Social Sciences (Z.B., J.-S.L., S.K.R., D.C.), Comprehensive Transplant Center (Z.B.), Institute for Healthcare Studies (Z.B., J.-S.L., D.C.), Department of Pediatrics (J.-S.L.), and Department of Psychiatry and Behavioral Sciences (S.K.R., D.C.), Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Division of Medical Oncology (A.V.R., A.P.A.), Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA Abstract Context. There has been some suggestion that the fatigue experienced by older cancer patients is more severe than that of younger cohorts; however, there is little empirical evidence to support this claim. Objectives. The goal of the present study was to determine the differential impact of age and cancer diagnosis on ratings of fatigue using a validated selfreport instrument. Methods. The Functional Assessment of Chronic Illness Therapy-Fatigue subscale consists of 13 items measuring fatigue experience and its impact on daily life, with scores ranging from 0 (severe fatigue) to 52 (no fatigue). Fatigue data were available from the U.S. general population (n ¼ 1075; 51.3% female, years) and a sample of mixed-diagnosis cancer patients (n ¼ 738; 64.3% female, years). General population participants were recruited using an Internet-based survey panel; patients with cancer were recruited from Chicago-area oncology clinics. Results. On average, the cancer patient group reported more severe fatigue than the general population group (36.9 vs. 46.6; F[1,1797] ¼ , P < 0.001). There was evidence for increased fatigue with age (F[6,719] ¼ 2.56, P < 0.02) among patients with cancer, but not in the general population (P ¼ 0.06). Furthermore, the group age interaction was not significant (P ¼ 0.44). Hemoglobin (Hgb) was treated as a covariate for 430 patients with available data; there was no main effect for age in this analysis. Portions of these findings were presented at the 2008 meeting of the Society for Behavioral Medicine. Funding source: A subset of the data analyzed for this study was collected as part of National Institutes of Health (NIH) R01 CA60068 (Principal Investigator: David Cella, PhD). Manuscript preparation supported in part by grant UL1RR from the National Center for Research Resources, NIH. Disclosures: Dr. Butt has received grant support from and served as a consultant for Ortho Biotech Ó 2010 U.S. Cancer Pain Relief Committee Published by Elsevier Inc. All rights reserved. and has served as a consultant for Johnson & Johnson. Dr. Cella has received grant support from Ortho Biotech. The other authors have no disclosures. Address correspondence to: Zeeshan Butt, PhD, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA. z-butt@northwestern.edu Accepted for publication: January 19, /$esee front matter doi: /j.jpainsymman
2 218 Butt et al. Vol. 40 No. 2 August 2010 Conclusion. Older adults, whether they had a cancer diagnosis, reported more fatigue than younger adults. These differences may be explained, in part, by Hgb level. Future research would be helpful to explore longitudinal changes in fatigue in the general population and guide fatigue management for the older cancer patient. J Pain Symptom Manage 2010;40:217e223. Ó 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. Key Words Fatigue, cancer, assessment, patient-reported outcome, hemoglobin Introduction Fatigue is the most prevalent symptom among individuals with cancer and may be because of the disease itself, its treatment, and/ or psychosocial variables. 1 Depending on the patient population and means of measuring fatigue, prevalence estimates among cancer patients are generally high, ranging from 60% to more than 90%. 1 Furthermore, in a large sample of patients with advanced cancer who have received chemotherapy, fatigue was spontaneously endorsed and ranked as the most important symptom that should be monitored. 2 Although common, cancer-related fatigue (CRF) remains poorly understood. 3 Patients may describe their experience of fatigue in terms of being exhausted, tired, weak, or slowed. In clinical practice, fatigue may be neglected or underdetected because of the fact that it is a subjective experience that is assessed by patient self-report. Treatment of CRF is further complicated by its multifactorial clinical manifestations, involving both psychological and physical components. One common cause of fatigue in the context of cancer is anemia. The decrease in hemoglobin (Hgb) leads to patient weakness, pallor, dyspnea, and fatigue. Given their nonspecific nature, symptoms of anemia are often difficult to attribute directly to anemia itself. However, the impact of low Hgb can be far reaching. 4,5 Important heath-related outcomes such as quality of life (QOL) can be enhanced with proper evaluation and treatment of fatigue and other anemia-related symptoms, 6 especially for the older adult. 7 There has been some suggestion that the fatigue experienced by older cancer patients is more severe than that of younger cohorts; however, there is little empirical evidence to support this claim. This is especially relevant in the case of the elderly, who may be more likely to consider fatigue as a normal part of the disease course with which they must suffer. In fact, our group has found no effect of age on CRF, when comparing patients older than 50 with those younger. 3 That said, few data are available to guide the assessment and treatment of CRF in older cancer patients. This lack of information is of considerable concern given that CRF can seriously compromise patients QOL and ability to function on a daily basis. 8 Given the general aging of the cancer population, and the importance of addressing fatigue in this population, we conducted a closer examination of the potential impact of age on CRF. Specifically, available cross-sectional data sets were used to investigate whether fatigue varied systematically as a function of both age and diagnosis. We hypothesized that cancer patients would report more fatigue than the general population and that this difference would be more pronounced for the older sample. That is, a statistical interaction between age and diagnosis was expected with respect to fatigue. Hgb values were available for a subset of patients, and it was hypothesized that differences in fatigue may be at least partly explained by this important clinical variable. Patient and Methods Sample Two existing data sets for this cross-sectional secondary data analysis were used. Full details on recruitment of the samples are found in the original publications. 3,9e12 Briefly, the first data set consisted of a large sample (n ¼ 1075) of individuals from the general population, randomly drawn to complete a series of
3 Vol. 40 No. 2 August 2010 Age-Associated Differences in Fatigue 219 questionnaires from more than 100,000 individuals enrolled in an Internet-based survey panel. 9 Data from several mixed-diagnosis cancer samples 3,10e12 comprised the second data set (n ¼ 738). In this second data set, patients were recruited from Chicago-area oncology clinics for studies on health-related QOL. All patients received some treatment for their cancer. Ethics Participants provided informed consent before data collection. Original data collection and informed consent procedures were approved by the appropriate institutional review board. Assessments All participants completed the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale. 10 The FACIT-F is a 13-item scale that asks respondents to rate statements regarding their fatigue experience and its impact on their daily lives. Sample items include I feel fatigued, I feel weak all over, and I feel listless (washed out). All items are rated on a 0 (not at all) to 4 (very much) scale. By scoring convention, after appropriate reverse scoring of 11 items, lower scores on the FACIT-F subscale indicate greater levels of fatigue. (A scoring template is available at Originally developed for use with cancer patients, 9,13 the scale has been successfully tested for use in the general population 3,9 and chronic anemia of aging. 7 To enhance the clinical usefulness of the FACIT-F subscale, Cella et al. 13 estimated a minimum clinically meaningful difference of 3 points by using both anchor- and distributionbased methods. Additionally, Eastern Cooperative Oncology Group (ECOG) performance ratings were available for all cancer patients and Hgb values, obtained within 30 days of fatigue ratings, were available for a subset of 430 cancer patients. Data Analysis Sociodemographic and clinical comparisons between the general population and patient groups were conducted using independent samples t-tests or c 2 tests, as appropriate. Analyses of variance (ANOVAs) and analysis of covariance were used to assess differences in fatigue across age categories. Statistical significance was set at P < All analyses were conducted using PASW Statistics 17 (SPSS, Chicago, IL). 14 Results Sample Characteristics As summarized in Table 1, the general population sample was years, 51% female, and primarily (84%) Caucasian. When asked to rate their health status on a 1 ( good ) to 5 ( bad ) scale, 56% of the sample responded with either a 1 or 2 rating. Cancer patients were years, 64% female, 88% Caucasian, and 79% self-reported ECOG performance status ratings of 0 or 1 (no symptoms to symptomatic, but ambulatory). 15 Breast (33%) and colorectal (12%) were the most common tumor types. Patients were older (t[1802] ¼ 17.3, P < 0.001) and more likely to be female (c 2 [1] ¼ 29.6, P < 0.001), compared with the general population sample. Fatigue As expected, cancer patients reported more fatigue (FACIT-F subscale ¼ ) than the general population sample ( ; F[1,1804] ¼ 329.2, P < 0.001). This finding was not because of the difference in gender ratios between the samples. Females reported more fatigue than males in the general population sample (t[1057] ¼ 3.7, P < 0.001), whereas males and females reported comparable levels of fatigue (t[724] < 1, P > 0.5) in the cancer sample. Additionally, when the entire sample (i.e., patients and general population) was subdivided using a binary age split (<65 vs. $65), older individuals reported more fatigue ( ) than those less than 65 years ( ; F[1,1797] ¼ 33.9, P < 0.001). Because an age cut off of 65 is arbitrary, the first age analysis was followed up with a mean comparison of fatigue by age, divided by decade. This analysis confirmed the association of age with fatigue (F[6,1797] ¼ 15.5, P < 0.001). Table 2 presents the mean fatigue scores by decade across the entire sample. Considered independently, diagnosis status and age were associated with increased fatigue, but the age trend becomes more consistent when the two subsamples are combined. Given the relatively low representation of the very young and the
4 220 Butt et al. Vol. 40 No. 2 August 2010 Table 1 Sociodemographic and Clinical Summary of Samples General Population (n ¼ 1075) Cancer Sample (n ¼ 738) Age (mean standard deviation), in years % Female Ethnicity, % Caucasian African American Hispanic Other Self-reported health status, % 1 ( good ) ECOG PSR PSR PSR PSR 3 5 ( bad ) PSR 4 FACIT-F subscale score Hgb d g/dl Tumor type, % d Breast 33.4 Colorectal 11.9 NHL 9.1 Ovarian 7.3 Prostate 5.1 Cancer stage, % I d 10.2 II d 24.6 III d 26.9 IV d 19.8 Note: ECOG Performance Status Rating: 0 ¼ fully active without restriction; 4 ¼ completely disabled, no self-care. Lower scores on the FACIT-F subscale indicate greater levels of fatigue. Cancer patients reported more severe fatigue than the general population (F[1,1804] ¼ 329.2, P < 0.001). NHL ¼ non-hodgkin s lymphoma; PSR ¼ performance status rating. very old in our cancer sample, we also tested the association of age separately for each group. In the cancer sample, there was a significant association (F[6,719] ¼ 2.56, P < 0.02) suggesting an increase in fatigue with age. The association of fatigue with age in the general population sample suggested a nonsignificant trend (F[6,1065] ¼ 2.03, P ¼ 0.06). A test of the interaction between sample (i.e., general population vs. cancer sample) and age required a test of both effects simultaneously. Considered conjointly, the main effect for sample (F[1,1797] ¼ 271.9, P < 0.001) and age (F[6,1797] ¼ 3.5, P < 0.01) remained; however, there was no support for a sample-age interaction (F[6,1707] ¼ 0.98, P ¼ 0.44). This lack of statistical interaction suggests that although cancer patients reported more fatigue than the general population, this difference did not increase significantly with age. Across the total sample, results from a regression analysis suggested that, with each additional decade, fatigue scores worsened (mean standard error) by points on the FACIT-F subscale (P < 0.001) (Fig. 1). Hemoglobin The potential impact of Hgb on fatigue ratings by age was investigated in the subset of cancer patients with available data (n ¼ 430). Of note, those patients with available Hgb values were not different from those patients without these data with respect to age (F[1,730] ¼ 0.001, P ¼ 0.98), sex (c 2 [1] ¼ 0.15, P ¼ 0.70), or FACIT-F subscale scores (F[1,730] ¼ 1.65, P ¼ 0.20). For those with available Hgb, the mean standard deviation values were within normal limits ( g/dl) and ranged from 7.0 to 19.3 g/dl. Hgb values were modestly associated with FACIT-F subscale scores (r ¼ 0.24, P < 0.001), in the expected direction. Men had higher Hgb values ( g/dl) than women ( g/dl; t[428] ¼ 3.15, P < 0.005). Interestingly, although there was no direct association of Hgb with age category
5 Vol. 40 No. 2 August 2010 Age-Associated Differences in Fatigue 221 Table 2 FACIT-F Subscale Scores by Population, Age, and for the Total Sample Population Age Category (Years) n % Mean Standard Deviation Minimum Maximum Cancer population 18e e e e e e þ Total General population 18e e e e e e þ Total Total 18e e e e e e þ Grand total Note: Total n does not equal 1813 because of missing data. FACIT-F subscale scores have a possible range of 0e52. Lower scores indicate greater levels of fatigue. A three-point change on the FACIT-F subscale has been shown to indicate clinically significant change in fatigue over time. 13 (F[6,429] ¼ 0.75, P ¼ 0.61), when Hgb was treated as a covariate in an ANOVA of the effect of age on fatigue ratings, Hgb explained significant variance in fatigue ratings (F[1,426] ¼ 24.15, P < 0.001) but age category (i.e., decade) did not (F[6,426] ¼ 1.63, P ¼ 0.14). Discussion The present cross-sectional study is notable in that it is the first to directly assess the statistical interaction between diagnosis and age on fatigue. Based on extant research, one might expect no or limited impact of age on CRF. 16 Cella et al. 3 found that people older than 50 years in the general population reported more fatigue than their younger counterparts on the 13-item FACIT-F subscale, but found no such age effect in the sample of anemic cancer patients. Similar analyses in other cancer clinical trials have failed to find a substantial effect of age on fatigue- and/or anemia-related QOL in cancer patients. 17,18 In contrast, the present analyses suggest that, as the decades accumulate, ratings of fatigue increase. However, increases in fatigue are not more pronounced for older patients with cancer compared with the general population. To the authors knowledge, this is the first published analysis that addresses this topic by considering cancer diagnosis and age concurrently. Across the overall sample of cancer patients and the general population, there is a statistically significant but somewhat modest increase in fatigue with age (1.27 points per decade on the FACIT-F subscale). Evaluation of the cancer and general population subgroups revealed that the increase in fatigue was more evident in the cancer sample. Hgb level appears to be a meaningful covariate and may be one of many factors that account for the age-associated differences in fatigue within the cancer sample. Low Hgb is common in the elderly, and the incidence increases with age. A recent analysis of U.S. national data using the National Health and Nutrition Examination Survey (1988e1994) suggests that the rate of anemia
6 222 Butt et al. Vol. 40 No. 2 August 2010 LESS fatigue FACIT-Fatigue Subscale MORE fatigue general population cancer sample Age Fig. 1. Fatigue in the general population and among cancer patients with advancing age. Bars represent means þ 95% confidence interval. Across both groups, there was evidence for increased fatigue with age (F[6,1797] ¼ 3.53, P < 0.01) but no group age interaction (P > 0.25). is 10%e11% for individuals older than 65 years and greater than 20% for individuals older than 85 years. 19 Thus, given that both anemia and cancer are common among the elderly, the question of age-associated fatigue changes is important to consider. Of course, CRF is not always because of low Hgb, 1,20,21 as suggested by the modest correlation between Hgb and FACIT-F subscale scores in the present analysis. CRF also may be brought on by the direct effects of the cancer, comorbid medical conditions, psychosocial factors, and/ or other treatment-related side effects 1,22,23 that were not assessed as part of this study. We focused on anemia as a potential explanatory variable in the present analysis because it was available for a significant portion of patients in this secondary data analysis. Additional data are needed to characterize the fatigue of the oldest cancer patients; our own sample was deficient in this age range. It also would be helpful to replicate the present findings in a sample of patients receiving more aggressive treatment regimens, as this would likely have significant impact on patient s reported fatigue. Although we were limited in terms of potential covariates and our cell sizes for the oldest old, our secondary data analysis was successful in generating hypotheses for future studies. Indeed, there is much research to be done to improve our understanding of how ratings of fatigue change with age. There remain questions to be answered with respect to changes in fatigue over time and the consequences of fatigue in aging adults. As individuals age, there may be a shift in their report of fatigue, because of some level of accommodation for or acceptance of reduced activity levels. 24 Fatigue also may impact the ability to participate in important life activities, which may be associated with inactivity, subsequent loss of muscle tone and weakness, and increased disability. 25 A sense of decreased ability to engage in physical activity also may have psychological consequences that should be monitored. 26 Certainly, additional research may be useful to explore longitudinal changes in fatigue to guide fatigue management for the older patient with and without cancer. References 1. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004;91:822e Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 2008;6:448e455.
7 Vol. 40 No. 2 August 2010 Age-Associated Differences in Fatigue Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528e Beghe C, Wilson A, Ershler WB. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):3Se10S. 5. Pujade-Lauraine E, Gascon P. The burden of anaemia in patients with cancer. Oncology 2004; 67(Suppl 1):1e4. 6. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4e Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc 2007;55:1557e Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979e Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366e Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63e Lai JS, Cella D, Dineen K, et al. An item bank was created to improve the measurement of cancer-related fatigue. J Clin Epidemiol 2005;58:190e Lai JS, Crane PK, Cella D. Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res 2006;15:1179e Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24: 547e PASW for Windows. Rel Chicago, IL: Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649e Butt Z, Cella D. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhepo) in clinical oncology: Scientific and clinical aspects of anemia in cancer. New York: Springer-Verlag, 2008; 369e Thome B, Dykes AK, Hallberg IR. Quality of life in old people with and without cancer. Qual Life Res 2004;13:1067e Aapro MS, Cella D, Zagari M. Age, anemia, and fatigue. Semin Oncol 2002;29:55e Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. The prevalence of anemia in persons age 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263e Lipman AJ, Lawrence DP. The management of fatigue in cancer patients. Oncology 2004;18:1527e Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;93e Mock V, Atkinson A, Barsevick AM, et al. Cancerrelated fatigue. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:1054e Levy M. Cancer fatigue: a review for psychiatrists. Gen Hosp Psychiatry 2008;30:233e Schwartz CE, Bode R, Repucci N, et al. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006;15:1533e Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146eM Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 2009;50:440e447.
The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer
40 Journal of Pain and Symptom Management Vol. 34 No. 1 July 2007 Original Article The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer Digant Gupta,
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced
More informationPublished Ahead of Print on September 5, 2008 as /theoncologist
The Oncologist Symptom Management and Supportive Care Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin
More informationMEASURING MEANING AND PEACE WITH THE FACIT-SP: DISTINCTION WITHOUT A DIFFERENCE?
MEASURING MEANING AND PEACE WITH THE FACIT-SP: DISTINCTION WITHOUT A DIFFERENCE? Eboni Hedgspeth, B.A. Charlie Reeve, Ph.D. Amy Peterman, Ph.D. University of North Carolina at Charlotte ACKNOWLEDGEMENTS
More informationFatigue in Cancer Patients Compared with Fatigue in the General United States Population
528 Fatigue in Cancer Patients Compared with Fatigue in the General United States Population David Cella, Ph.D. 1 Jin-shei Lai, Ph.D. 1 Chih-Hung Chang, Ph.D. 1 Amy Peterman, Ph.D. 1 Mitchell Slavin, Pharm.D.
More informationSymptom Management and Supportive Care
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Symptom Management and Supportive Care Early Intervention with
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationI Get Tired for No Reason: A Single Item Screening for Cancer-Related Fatigue
Vol. 22 No. 5 November 2001 Journal of Pain and Symptom Management 931 Original Article I Get Tired for No Reason: A Single Item Screening for Cancer-Related Fatigue Kenneth L. Kirsh, MS, Steven Passik,
More informationPhysical, Emotional, and Social Health Differences Between Posttreatment Young Adults With Cancer and Matched Healthy Controls
Physical, Emotional, and Social Health Differences Between Posttreatment Young Adults With Cancer and Matched Healthy Controls John M. Salsman, PhD 1,2 ; Sofia F. Garcia, PhD 1,2,3 ; Betina Yanez, PhD
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationReliability and Validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module
2090 The PedsQL in Pediatric Cancer Reliability and Validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module James W. Varni, Ph.D. 1,2
More informationMultidimensional fatigue and its correlates in hospitalized advanced cancer patients
Chapter 5 Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Michael Echtelda,b Saskia Teunissenc Jan Passchierb Susanne Claessena, Ronald de Wita Karin van der Rijta
More informationRadiotherapy-Associated Anemia: The Scope of the Problem
Radiotherapy-Associated Anemia: The Scope of the Problem LOUIS B. HARRISON, DANIEL SHASHA, CAROL WHITE, BEVERLY RAMDEEN Department of Radiation Oncology, Beth Israel Medical Center, St. Luke s-roosevelt
More informationFrequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
Year: 2014; Volume: 1; Issue: 1 Article ID: CR14 02; Pages: 1-6 Advances in Cancer Research & Therapy Research Article Frequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
More informationCancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka
Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise
More informationPerformance of PROMIS and Legacy Measures Among Advanced Breast Cancer Patients and Their Caregivers
Performance of PROMIS and Legacy Measures Among Advanced Breast Cancer Patients and Their Caregivers Alla Sikorskii, PhD Department of Psychiatry Department of Statistics and Probability Michigan State
More informationPatient and health care provider perceptions of cancer-related fatigue and pain
Support Care Cancer (2016) 24:4357 4363 DOI 10.1007/s00520-016-3275-2 ORIGINAL ARTICLE Patient and health care provider perceptions of cancer-related fatigue and pain Loretta A. Williams 1 & Chet Bohac
More informationManagement of Cancer Symptoms: Pain, Depression, and Fatigue
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 61 Management of Cancer Symptoms: Pain, Depression, and Fatigue Summary Overview This evidence report on Management
More informationBrief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia
Support Care Cancer (2015) 23:1355 1364 DOI 10.1007/s00520-014-2484-9 ORIGINAL ARTICLE Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia John
More informationQuality-of-Life and Health Benefits of Early Treatment of Mild Anemia
1909 Quality-of-Life and Health Benefits of Early Treatment of Mild Anemia A Randomized Trial of Epoetin alfa in Patients Receiving Chemotherapy for Hematologic Malignancies David J. Straus, MD 1 Marcia
More informationValidation Study of the Chinese Version of the Brief Fatigue Inventory (BFI-C)
322 Journal of Pain and Symptom Management Vol. 27 No. 4 April 2004 Original Article Validation Study of the Chinese Version of the Brief Fatigue Inventory (BFI-C) Xin Shelley Wang, MD, Xi-Shan Hao, MD,
More informationFurther Validation of the Multidimensional Fatigue Symptom Inventory-Short Form
14 Journal of Pain and Symptom Management Vol. 27 No. 1 January 2004 Original Article Further Validation of the Multidimensional Fatigue Symptom Inventory-Short Form Kevin D. Stein, PhD, Paul B. Jacobsen,
More informationPsychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer
Support Care Cancer (2011) 19:657 666 DOI 10.1007/s00520-010-0878-x ORIGINAL ARTICLE Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationParsing Depression From Fatigue in Patients with Cancer Using the Fatigue Symptom Inventory
52 Journal of Pain and Symptom Management Vol. 42 No. 1 July 2011 Original Article Parsing Depression From Fatigue in Patients with Cancer Using the Fatigue Symptom Inventory Lara Traeger, PhD, Ilana M.
More information282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013
282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013 Brief Report Comparing the Retrospective Reports of Fatigue Using the Fatigue Symptom Index With Daily Diary Ratings in Women Receiving
More informationSources of Comparability Between Probability Sample Estimates and Nonprobability Web Sample Estimates
Sources of Comparability Between Probability Sample Estimates and Nonprobability Web Sample Estimates William Riley 1, Ron D. Hays 2, Robert M. Kaplan 1, David Cella 3, 1 National Institutes of Health,
More informationHealth State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations
Volume 11 Number 7 2008 VALUE IN HEALTH Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations Andrew Lloyd, DPhil, 1 Patricia van Hanswijck de Jonge, PhD, 2 Scott
More informationDifferences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study
Cataldo et al. BMC Cancer 2013, 13:6 RESEARCH ARTICLE Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study Open Access Janine K Cataldo 1, Steven
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationA Randomized, Double-Blind, Placebo- Controlled Trial Assessing the Impact of Dexamphetamine on Fatigue in Patients with Advanced Cancer
Vol. 37 No. 4 April 2009 Journal of Pain and Symptom Management 613 Original Article A Randomized, Double-Blind, Placebo- Controlled Trial Assessing the Impact of Dexamphetamine on Fatigue in Patients
More informationPsychometric Properties of the Brief Fatigue Inventory in Greek Patients with Advanced Cancer
Vol. 36 No. 4 October 2008 Journal of Pain and Symptom Management 367 Original Article Psychometric Properties of the Brief Fatigue Inventory in Greek Patients with Advanced Cancer Kyriaki Mystakidou,
More informationOriginal Article. Key Words Ambulatory monitoring, circadian rhythm, fatigue, motor activity, neoplasms, sleep disorders
Vol. 32 No. 3 September 2006 Journal of Pain and Symptom Management 245 Original Article Comparison Between Fatigue, Sleep Disturbance, and Circadian Rhythm in Cancer Inpatients and Healthy Volunteers:
More informationUsing PROMIS to Assess Quality of Life for Children with Brain Tumors
Using PROMIS to Assess Quality of Life for Children with Brain Tumors Jin-Shei Lai 1,1 Jennifer Beaumont 1, Cindy Nowinski 1, Stewart Goldman 2 1 Medical Social Sciences, Northwestern University 2 Ann
More informationGeriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationL-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study
622 Journal of Pain and Symptom Management Vol. 37 No. 4 April 2009 Original Article L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled
More informationCancer-Related Fatigue: The Scale of the Problem
Cancer-Related Fatigue: The Scale of the Problem Maarten Hofman, a Julie L. Ryan, a,b Colmar D. Figueroa-Moseley, a,c Pascal Jean-Pierre, a,d Gary R. Morrow a,e a Department of Radiation Oncology, b Department
More informationChanging Patient Perceptions of the Side Effects of Cancer Chemotherapy
155 Changing Patient Perceptions of the Side Effects of Cancer Chemotherapy Nadége Carelle, R.Ph. 1 Estelle Piotto, 1 Agnés Bellanger, Pharm.D. 1 Jerome Germanaud, 1 Alain Thuillier, M.D. 1 David Khayat,
More informationRelationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy
888 Relationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy Jeffrey Crawford, M.D. 1 David Cella, Ph.D. 2 Charles
More informationPROMIS: What is it, Why Use it, and How to Advance the Mission of Integrative Oncology
PROMIS: What is it, Why Use it, and How to Advance the Mission of Integrative Oncology David Cella, PhD Professor and Chair, Dept. of Medical Social Sciences Northwestern University, Feinberg School of
More informationThe American Cancer Society National Quality of Life Survey for Caregivers
The American Cancer Society National Quality of Life Survey for Caregivers Rachel S. Cannady Strategic Director, Cancer Caregiver Support Atlanta, GA Agenda Definition and prevalence of cancer survivorship
More informationSource of effectiveness data The estimate for final outcomes was based on a synthesis of completed studies.
Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia Cremieux P, Finkelstein S N, Berndt E R, Crawford J, Slavin
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationLongitudinal Follow-Up Study Using the Distress and Impact Thermometer in an Outpatient Chemotherapy Setting
236 Journal of Pain and Symptom Management Vol. 43 No. 2 February 2012 Original Article Longitudinal Follow-Up Study Using the Distress and Impact Thermometer in an Outpatient Chemotherapy Setting Takashi
More informationThe Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors
http://dx.doi.org/ SCIENTIFIC INVESTIGATIONS The Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors 3 5,6 5 ; 2 1 Department of Oncological Sciences, Icahn School
More informationSocial Participation Among Veterans With SCI/D: The Impact of Post Traumatic Stress Disorder
Social Participation Among Veterans With SCI/D: The Impact of Post Traumatic Stress Disorder Bella Etingen, PhD 1 ;Sara M. Locatelli, PhD 1 ;Scott Miskevics, BS 1 ; Sherri L. LaVela, PhD, MPH, MBA 1,2
More informationOn Bridging the Theory and Measurement of Frailty
On Bridging the Theory and Measurement of Frailty K. Bandeen-Roche 1, Ph.D., Q.-L. Xue 2, Ph.D., L. Ferrucci 3, MD, Ph.D., J. Walston 2, MD, J. M. Guralnik 4, MD, Ph.D., P. Chaves 2, MD, Ph.D., S. L. Zeger
More informationA 3-Factor Model for the FACIT-Sp
A 3-Factor Model for the FACIT-Sp Reference: Canada, Murphy, Fitchett, Peterman, Schover. Psycho-Oncology. Published Online: Dec 19, 2007; DOI: 10.1002/pon.1307. Copyright John Wiley & Sons Ltd. Investigators
More informationValidation of the Pediatric Functional Assessment of Cancer Therapy Questionnaire (Version 2.0) in Brain Tumor Survivors Aged 13 Years and Older
Vol. 40 No. 4 October 2010 Journal of Pain and Symptom Management 559 Original Article Validation of the Pediatric Functional Assessment of Cancer Therapy Questionnaire (Version 2.0) in Brain Tumor Survivors
More informationTREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018
TREATMENT CONSIDERATIONS IN CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Discuss key considerations that influence patient outcomes Highlight the importance of patients quality
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationQuality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia
Critical Reviews in Oncology/Hematology 69 (2009) 168 174 Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia Shabbir M.H. Alibhai a,b,d,e,, Marc Leach a, Vikas
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationASSOCIATION FOR ACADEMIC SURGERY Quality of Life Assessment in Postoperative Patients with Upper GI Malignancies
Journal of Surgical Research 163, 40 46 (2010) doi:10.1016/j.jss.2010.04.057 ASSOCIATION FOR ACADEMIC SURGERY Quality of Life Assessment in Postoperative Patients with Upper GI Malignancies Jane R. Schubart,
More informationThe Underrecognized Role of Impaired Muscle Function in Cancer-Related Fatigue
Marquette University e-publications@marquette Exercise Science Faculty Research and Publications Exercise Science, Department of 7-1-2010 The Underrecognized Role of Impaired Muscle Function in Cancer-Related
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationResearch Article The Relationship of Allergy Severity to Depressive and Anxious Symptomatology: The Role of Attitude toward Illness
International Scholarly Research Network ISRN Allergy Volume 2011, Article ID 765309, 4 pages doi:10.5402/2011/765309 Research Article The Relationship of Allergy Severity to Depressive and Anxious Symptomatology:
More informationReliable data on the costs and outcomes of different
The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis Arnold Barnett, PhD; Howard Birnbaum, PhD; Pierre-Yves Cremieux, PhD; A. Mark Fendrick, MD; and Mitchell Slavin, PharmD
More informationKEYWORDS: symptoms, symptom assessment, cancer, symptom management, M. D. Anderson Symptom Inventory, MDASI.
The Symptom Burden of Cancer: Evidence for a Core Set of Cancer-Related and Treatment-Related Symptoms From the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns Study Charles S.
More informationIntegrating Palliative and Oncology Care in Patients with Advanced Cancer
Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be
More informationEfficacy of Short-Term Life-Review Interviews on the Spiritual Well-Being of Terminally Ill Cancer Patients
Vol. 39 No. 6 June 2010 Journal of Pain and Symptom Management 993 Original Article Efficacy of Short-Term Life-Review Interviews on the Spiritual Well-Being of Terminally Ill Cancer Patients Michiyo Ando,
More informationASCO Advanced Course
EVALTUATION OF AGING: PHYSIOLOGIC AGE LODOVICO BALDUCCI M.D. H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE NCCN GUIDELINES SOME FORM OF GERIATRIC ASSESSMENT FOR INDIVIDUALS AGED 70+ ADJUSTMENT OF
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationOncologist. The. Genitourinary Cancer: Renal, Bladder, and Testicular
The Oncologist Genitourinary Cancer: Renal, Bladder, and Testicular Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationFATIGUE SYMPTOM INVENTORY BIBLIOGRAPHY. Prepared by Kristine A. Donovan, Ph.D. and Paul B. Jacobsen, Ph.D.
FATIGUE SYMPTOM INVENTORY BIBLIOGRAPHY Prepared by Kristine A. Donovan, Ph.D. and Paul B. Jacobsen, Ph.D. 1. Broeckel J, Jacobsen P, Horton J, Balducci L, Lyman G. Characteristics and correlates of fatigue
More informationa persistent symptom, a subjective feeling of physical, emotional or cognitive tiredness or exhaustion related to cancer or its treatment that is not
a persistent symptom, a subjective feeling of physical, emotional or cognitive tiredness or exhaustion related to cancer or its treatment that is not proportional to the recently performed activity, and
More informationValidation of a Modified Rotterdam Symptom Checklist for Use with Cancer Patients in the United States
Vol. 26 No. 5 November 2003 Journal of Pain and Symptom Management 975 Original Article Validation of a Modified Rotterdam Symptom Checklist for Use with Cancer Patients in the United States Kevin D. Stein,
More informationCost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
FORMULARY MANAGEMENT Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia PIERRE Y. CRÉMIEUX, PhD; JOHN M. FASTENAU, RPh, MPH; GEORGE KOSICKI, PhD;
More informationJune 12, Dear Dr. Phurrough:
June 12, 2007 Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Mail Stop C1-09-06 7500 Security Boulevard Baltimore, MD 21244 Dear Dr. Phurrough:
More informationCOGNITIVE FUNCTION. PROMIS Pediatric Item Bank v1.0 Cognitive Function PROMIS Pediatric Short Form v1.0 Cognitive Function 7a
COGNITIVE FUNCTION A brief guide to the PROMIS Cognitive Function instruments: ADULT PEDIATRIC PARENT PROXY PROMIS Item Bank v1.0 Applied Cognition - Abilities* PROMIS Item Bank v1.0 Applied Cognition
More informationProspective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease
Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the
More informationHEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017
HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths
More informationFatigue in cancer patients treated with cytotoxic drugs
J Oncol Pharm Practice (2006) 12: 155164 Fatigue in cancer patients treated with cytotoxic drugs Per Hartvig PharmD, PhD 1 Johan Aulin MSc in pharmacy 1,3 Matilda Hugerth MSc in pharmacy 3 Sofia Wallenberg
More information36-Item Short Form Survey (SF-36) Versus Gait Speed as a Predictor of Preclinical Mobility Disability in Older Women
36-Item Short Form Survey (SF-36) Versus Gait Speed as a Predictor of Preclinical Mobility Disability in Older Women May 2018 WHI Investigator Meeting MS 2744 J Am Geriatr Soc. 2018 Feb 10. doi: 10.1111/jgs.15273.
More informationDOI: /theoncologist This information is current as of December 12, 2007
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition Gregory A. Curt, William Breitbart, David Cella, Jerome E. Groopman, Sandra J. Horning, Loretta M. Itri,
More informationChanges Over Time in Occurrence, Severity, and Distress of Common Symptoms During and After Radiation Therapy for Breast Cancer
98 Journal of Pain and Symptom Management Vol. 45 No. June Original Article Changes Over Time in Occurrence, Severity, and Distress of Common Symptoms During and After Radiation Therapy for Breast Cancer
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationSingle- vs. Multiple-Item Instruments in the Assessment of Quality of Life in Patients with Advanced Cancer
564 Journal of Pain and Symptom Management Vol. 39 No. 3 March 2010 Original Article Single- vs. Multiple-Item Instruments in the Assessment of Quality of Life in Patients with Advanced Cancer Shirley
More informationSurvive and Thrive: Palliative Care. Gordon J. Wood, MD, MSCI, FAAHPM September 9, 2017
Survive and Thrive: Palliative Care Gordon J. Wood, MD, MSCI, FAAHPM September 9, 2017 Objectives Define Palliative Care Differentiate Palliative Care from Hospice Describe the history of Palliative Care
More informationApproximately 60% of cancers are diagnosed in persons
Physical Performance and Subsequent Disability and Survival in Older Adults with Malignancy: Results from the Health, Aging and Body Composition Study HeidiD.Klepin,MD,MS, Ann M. Geiger, PhD, w JanetA.Tooze,PhD,
More informationThe Utility of Screening in the Design of Trials for Symptom Management in Cancer
606 Journal of Pain and Symptom Management Vol. 38 No. 4 October 2009 Original Article The Utility of Screening in the Design of Trials for Symptom Management in Cancer Sangchoon Jeon, PhD, Charles W.
More informationPhase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients
DOI 10.1007/s00520-010-0823-z SHORT COMMUNICATION Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients Amy P. Abernethy & James E. Herndon II & April Coan & Tina Staley &
More informationMultidimensional Measurement of Fatigue in Advanced Cancer Patients in Palliative Care: An Application of the Multidimensional Fatigue Inventory
Vol. 31 No. 6 June 2006 Journal of Pain and Symptom Management 533 Original Article Multidimensional Measurement of Fatigue in Advanced Cancer Patients in Palliative Care: An Application of the Multidimensional
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationA Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY
More informationGeriatrics and Cancer Care
Geriatrics and Cancer Care Roger Wong, BMSc, MD, FRCPC, FACP Postgraduate Dean of Medical Education Clinical Professor, Division of Geriatric Medicine UBC Faculty of Medicine Disclosure No competing interests
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationGetting Fit for Transplant. Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine
Getting Fit for Transplant Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine No Disclosures. Objectives Describe frailty in transplant Discuss the role of physical
More informationFatigue Bigorio Professor Paddy Stone
Fatigue Bigorio 2013 Professor Paddy Stone Overview What is fatigue? How can fatigue be assessed? How can fatigue be treated? Guidelines? Fatigue is a subjective, unpleasant symptom which incorporates
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationAnemia is a common complication of cancer. Symptom burdens related to chemotherapy-induced anemia in stage IV cancer.
Original Report Symptom burdens related to chemotherapy-induced anemia in stage IV cancer Leila Family, PhD, a Hairong Xu, PhD, b Kim Cannavale, MPH, c Bhakti Mehta, MD, b Andrew Pourmoussa, MD, d Lanfang
More informationExplanatory Attributions of Anxiety and Recovery in a Study of Kava
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 10, Number 3, 2004, pp. 556 559 Mary Ann Liebert, Inc. Explanatory Attributions of Anxiety and Recovery in a Study of Kava KURIAN C. ABRAHAM,
More informationPrincipal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (
Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:
More informationReliability and Validity of the Divided
Aging, Neuropsychology, and Cognition, 12:89 98 Copyright 2005 Taylor & Francis, Inc. ISSN: 1382-5585/05 DOI: 10.1080/13825580590925143 Reliability and Validity of the Divided Aging, 121Taylor NANC 52900
More informationCancer-related fatigue: clinical practice versus practice guidelines
Support Care Cancer (2011) 19:531 538 DOI 10.1007/s00520-010-0848-3 ORIGINAL ARTICLE Cancer-related fatigue: clinical practice versus practice guidelines Doranne L. Hilarius & Paul H. Kloeg & Elsken van
More information